{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-001705","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2023-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.138143+00:00","generated_at":"2026-06-20T18:43:23.912468+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immunome partners with AbbVie for up to 10 novel oncology targets; $30M upfront","bullets":["Immunome grants AbbVie options to purchase up to 10 novel antibody-target pairs from three tumor types.","Upfront payment of $30M; potential platform access payments up to $70M based on research continuations.","Development and first commercial sale milestones up to $120M per target; sales milestones and tiered royalties low single digits.","Research term at least 66 months; exclusive to AbbVie for selected tumor types during term.","Collaboration leverages Immunome's Discovery Engine; Immunome retains platform technology rights."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-001705","json":"https://secwatch.observer/filing/0001104659-23-001705.json","markdown":"https://secwatch.observer/filing/0001104659-23-001705.md","text":"https://secwatch.observer/filing/0001104659-23-001705.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000110465923001705/0001104659-23-001705-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000110465923001705/tm231749d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:43:23.912468+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a0381c52598db8be9b86032aa0ed457235082609","claim":"Immunome Inc. entered into Collaboration Agreement with AbbVie Global Enterprises Ltd. valued at $30 million (effective 2023-01-04).","evidence_excerpt":"On January 4, 2023, Immunome, Inc. (the “ Company ”) entered into a collaboration and option agreement (“ Collaboration Agreement ”) with AbbVie Global Enterprises Ltd. (“ AbbVie ”),","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472012/000110465923001705/0001104659-23-001705-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"AbbVie Global Enterprises Ltd."},{"label":"Value","value":"$30 million"},{"label":"Effective","value":"2023-01-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}